Ameritox

From Wikipedia, the free encyclopedia - View original article

TypePrivate
IndustryUrine Drug Monitoring
FoundedBaltimore, MD
HeadquartersBaltimore, MD, United States
Key peopleAncelmo E. Lopes (CEO), Todd Garner (CFO), Jay Zimmerman (COO), Dr. Harry Leider, MD FACPE (Senior Vice President and Chief Medical Officer), Jay Zimmerman (COO), Joel McEndree (Vice President, Intellectual Property and Program Development), Dr. Ronald C. Baker (Vice President, Toxicology), Dr. James E. Bourland (Laboratory Director), Lori Overstreet (Senior Vice President Marketing and New Products), David Mack (Senior Vice President Human Resources), Regina Morano (Corporate Compliance Officer & Vice President)
Websitehttp://www.ameritox.com
 
Jump to: navigation, search
TypePrivate
IndustryUrine Drug Monitoring
FoundedBaltimore, MD
HeadquartersBaltimore, MD, United States
Key peopleAncelmo E. Lopes (CEO), Todd Garner (CFO), Jay Zimmerman (COO), Dr. Harry Leider, MD FACPE (Senior Vice President and Chief Medical Officer), Jay Zimmerman (COO), Joel McEndree (Vice President, Intellectual Property and Program Development), Dr. Ronald C. Baker (Vice President, Toxicology), Dr. James E. Bourland (Laboratory Director), Lori Overstreet (Senior Vice President Marketing and New Products), David Mack (Senior Vice President Human Resources), Regina Morano (Corporate Compliance Officer & Vice President)
Websitehttp://www.ameritox.com

Ameritox is a company that provides physicians with urine drug monitoring and reporting services. Headquartered in Baltimore, Maryland, the company also has offices and CLIA-certified laboratories in Midland, Texas and Greensboro, North Carolina.

Ameritox offers urine drug testing and reporting services to help physicians determine if their chronic pain patients are taking their pain medications as prescribed. Physicians use this information to identify potential medication misuse and abuse, and make more informed decions. Ameritox’s customer service and patient management support tools permit physicians to integrate medication monitoring into their practice.

Dr. Harry Leider, MD FACPE, Ameritox's Senior Vice President and Chief Medical Officer, also serves as the President and Chairman of the Board for the American College of Physician Executives (ACPE) - the nation's oldest and largest health care organization for physician executives.

Contents

History

Ameritox Ltd. was founded in 1996 in Midland, Texas as Universal Toxicology Laboratories (UTL), a federally certified drug testing facility and medical examiner toxicology laboratory.[1]

UTL identified a growing need for a more detailed way of monitoring the use of long-term pain medications used by patients. The company became Ameritox Ltd. in 2003. Today, Ameritox claims to be the nation's largest provider of pain medication monitoring solutions for physicians.[2]

Civil Settlement

Tampa, FL - In 2010, the United States Attorney Robert E. O’Neill and Ameritox, Ltd. reached an agreement to pay $16.3 million in a civil settlement that addressed allegations that it paid kickbacks to providers in order to induce them to refer Medicare business.

Ameritox also entered into a 5-year Corporate Integrity Agreement (CIA) with the Department of Health & Human Services Office of Inspector General (HHS-OIG). Among other things, the CIA requires the company to engage an independent review organization to scrutinize its contractual relationships.[3]

Products

Rx Guardian CD

Rx Guardian CD SM is now part of the Rx Guardian SM process. Rx Guardian CD SM features a unique reference database supported by a proprietary normalization algorithm. Patients’ normalized results are compared against the reference database, giving added confidence in assessing whether patients are taking their medications correctly.

Research

High Rates of Inappropriate Drug Use in the Chronic Pain Population

Ameritox and the Jefferson School of Population Health at Thomas Jefferson University conducted a national study to determine the rates of inappropriate use, and likely abuse, misuse and diversion of opioids among chronic pain patients, as measured by urine drug testing in the clinical setting. The results showed that 75% of patients in the study may not have been taking their pain medication consistent with their prescribed regimen.[4]

References

External links